

INNOCAN PHARMA CORPORATION

TO: Ziv Haft, Certified Public Accountants (Isr.), BDO Member Firm

AND TO: Brightman Almagor Zohar & Co., Certified Public Accountants (a firm in the Deloitte Global Network)

AND TO: Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Autorité des marchés financiers
Financial and Consumer Services Commission of New Brunswick
Nova Scotia Securities Commission
Financial and Consumer Services Division of Prince Edward Island
Office of the Superintendent of Securities Service Newfoundland and Labrador
Office of the Yukon Superintendent of Securities
Office of the Superintendent of Securities, Northwest Territories
Nunavut Securities Office

RE: Notice of Change of Auditor

Innocan Pharma Corporation (the “**Corporation**”) hereby delivers the following notice in accordance with Section 4.11 of National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”):

1. The Corporation has approved a change of its auditor from Ziv Haft, Certified Public Accountants (Isr.), BDO Member Firm (the “**Former Auditor**”) to Brightman Almagor Zohar & Co., Certified Public Accountants (a firm in the Deloitte Global Network) (the “**Successor Auditor**”). On June 3rd, 2024, the Corporation asked the Former Auditor to resign. The Former Auditor submitted their resignation effective June 25th, 2024. Pursuant to the *Canada Business Corporations Act*, the directors are entitled to fill any vacancy in the office of auditor. The Successor Auditor has agreed to its appointment as the Corporation’s new auditor.
2. The Former Auditor resigned at the Corporation’s request.
3. The making of the Corporation’s request for the Former Auditor to resign as auditor of the Corporation and the appointment of the Successor Auditor as auditor of the Corporation were considered and approved by the audit committee of the board of directors of the Corporation and by the board of directors of the Corporation.
4. There were no modified opinions issued by the Former Auditor in connection with its audit of the Corporation’s two most recently completed fiscal years ended December 31, 2023 and 2022 nor the period from the most recently completed fiscal year for which the Former Auditor issued an audit report in respect of the Corporation and the date of this Notice.
5. There are no “reportable events”, as defined in NI 51-102.

DATED June 27, 2024.

INNOCAN PHARMA CORPORATION

Per: “Nelson Halpern”
Name: Nelson Halpern
Title: Chief Financial Officer